Section Arrow
OABI.NASDAQ
- OmniAb
Quotes are at least 15-min delayed:2025/03/28 05:29 EDT
Last
 2.47
+0.04 (+1.65%)
Day High 
2.47 
Prev. Close
2.43 
1-M High
3.54 
Volume 
636.97K 
Bid
2.05
Ask
2.48
Day Low
2.39 
Open
2.42 
1-M Low
2.2308 
Market Cap 
296.79M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.76 
20-SMA 3.06 
50-SMA 3.28 
52-W High 5.5429 
52-W Low 2.2308 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.61/-0.36
Enterprise Value
316.17M
Balance Sheet
Book Value Per Share
2.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
26.39M
Operating Revenue Per Share
0.54
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 05:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.